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SUMMARY
Objective: The effectiveness of neonatal screening for reducing morbimortality in chil-
dren with congenital adrenal hyperplasia (CAH) is the main justification for its imple-
mentation. One of the challenges for its implementation is to determine the cutoff value 
for laboratory measurement of 17-hydroxyprogesterone (17OHP) with appropriate 
cost-effectiveness. This study identified factors affecting the results of the pilot project of 
newborn screening for CAH, performed in the state of Minas Gerais, Brazil. Methods: 
Neonatal screening performed between September, 2007 and May, 2008, with 17OHP 
measurements performed in blood samples taken from the heel (filter paper), on the 5th 
day of life, processed by the UMELISA 17-OH Progesterona NEONATAL® method. The 
cutoff value was 80 and 160 nmol/L for healthy children or not, respectively. Results: The 
incidence of CAH was 1:19,939 in 159,415 children screened. The 99th percentile (p99) 
of 17OHP in the first sample was 108 nmol/L. In 13,298 newborns whose weight had 
been reported, the p99 of 17OHP were, respectively: 344 nmol/L for weight < 1,500 g; 
260 nmol/L for weight between 1,500 and 1,999 g; 221 nmol/L for weight between 
2,000 and 2,499 g; 109 nmol/L for weight ≥ 2,500g. The rate of recall for medical consul-
tation was 0.31%. The test sensitivity was 100%, specificity was 99.6%, and the positive 
predictive value was 2.2%. By adjusting the cutoff values of 17OHP to 110 nmol/L and 
220 nmol/L, a 76% decrease in consultation referrals was projected. Conclusion: The use 
of 17OHP cutoff values, considering birth weight, was a cost-effective measure to reduce 
false positives. The results of this pilot study suggest that screening for CAH might ben-
efit the pediatric population.
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INTRODUCTION
Neonatal screening tests have changed the course of sev-
eral diseases, by allowing children to be treated even be-
fore the onset of clinical manifestations, thus providing 
significant improvement in prognosis. For the inclusion of 
a disease in a neonatal screening program, certain require-
ments must be met: the disease in question must be rela-
tively frequent in the screened population, have significant 
morbidity and mortality if not treated early, and show a 
beneficial response to treatment1-3. 
Congenital adrenal hyperplasia (CAH) due to 21-hy-
droxylase (21-OH) enzyme deficiency is related to altera-
tions in cortisol biosynthesis, and has a worldwide inci-
dence of 1:15,000 live births4. Approximately 65% to 75% 
of these children have the classic salt-wasting form, which 
is characterized by higher morbidity and mortality if not 
treated early; newborn females have ambiguous genitalia 
at birth, which may lead to incorrect social gender as-
signment, depending on the severity of the condition. In 
males, however, the first manifestation observed is the salt-
loss crisis, with risk of death within the first weeks of life. 
An early diagnosis is, therefore, essential to reduce these 
occurrences. 
The screening programs for CAH aim primarily at the 
early diagnosis of the salt-wasting form, which is more se-
vere and harmful. The accumulation of the 17-hydroxypro-
gesterone (17OHP) metabolite, which occurs due to a defi-
ciency of 21-OH, can be identified by its measurement on 
filter paper blood spots. What is observed, however, is that 
increases in this metabolite may occur in newborns with-
out CAH under stress situations due to maternal or neona-
tal factors. Premature infants without CAH also may have 
elevated levels of 17OHP at the screening, due to higher 
concentrations of conjugated steroids, and relative renal 
system immaturity with insufficient excretory function5,6.  
Thus, the main challenge to screening for CAH is to 
determine a cutoff value for 17OHP that will result in ad-
equate cost-benefit. The use of different reference values 
according to gestational age or birth weight and age at col-
lection are strategies often adopted to make the screening 
process feasible, mainly regarding the reduction of false-
positive results7-10.   
Aiming to contribute to the advancement of CAH 
screening programs, data from a pilot CAH project, con-
ducted in the state of Minas Gerais (MG), were analyzed. 
The results can contribute to the discussion on the feasibil-
ity of establishing new neonatal screening programs to be 
implemented as routine. 
METHODS
Screening for CAH was included in the newborn screen-
ing program of the state of Minas Gerais (Programa de 
Triagem Neonatal – PETN-MG) as a pilot project, taking 
advantage of the already consolidated structure for neo-
natal screening. The Action and Research Center for Di-
agnostic Support (Núcleo de Ações e Pesquisa em Apoio 
Diagnóstico - NUPAD), a complementary organ of the 
School of Medicine of Universidade Federal de Minas 
Gerais (UFMG) was accredited in 2001 by the Ministry 
of Health as a reference service for neonatal screening in 
Minas Gerais. Since 2003, the PETN-MG has been re-
sponsible for the screening of the four selected diseases 
- phenylketonuria, congenital hypothyroidism, cystic fi-
brosis, and hemoglobinopathies, for 853 municipalities11.
The study was approved by the Ethics in Research 
Committees of the UFMG and of the Health Secretariat 
of Belo Horizonte City Council. The families gave their 
informed consent for participation in the project. 
The collection of blood samples was performed on the 
heel of newborns, in the basic units of the public health 
network of municipalities as part of the Guthrie or “heel 
prick” test, preferably on the 5th day of life.
A total of 159,415 children were screened between 
September, 2007 and May, 2008, corresponding to nearly 
all newborns in the period, as the program covers nearly 
100% of the municipalities of the state of Minas Gerais. 
The measurements of 17OHP on filter paper samples, 
sent to NUPAD by the municipalities, were performed 
using the UMELISA 17OH Progesterone NEONATAL® 
(Immunoassay Center, Havana, Cuba). The cutoff value 
reported by the kit manufacturer (55 nmol/L) was modi-
fied after analysis of preliminary results to assess the ad-
equacy of this value in the studied population. The 99th 
percentile (p99) of 17OHP values was established as 
the reference for this population of 15,000 initial sam-
ples. The value of 80 nmol/L was adopted as the nor-
mal range based on these results (p99 = 82.21 nmol/L). 
Children with basal 17OHP levels > 160 nmol/L were im-
mediately called for medical consultation. Children with 
levels between 80 and 160 nmol/L were retested, also on 
filter paper. The finding of a second sample > 80 nmol/L 
automatically generated a request for medical consulta-
tion (Figure 1).  
Based on the assessment of the results obtained until 
November 29, 2007 with a large number of positive tests 
in children maintained in maternity wards, a specific 
cutoff of 160 nmol/L was adopted for non-healthy new-
borns classified as low birth weight (weighing less than 
2,500 grams) or preterm (gestational age less than 37 
weeks). Information on birth weight was provided at the 
time of collection. In the absence of the reported weight, 
newborns were evaluated using the cutoff of 80 nmol/L. 
All children with a positive screening were referred 
for follow-up at the pediatric outpatient endocrinology 
clinic at the Hospital das Clínicas of the UFMG in Belo 
Horizonte (HC-UFMG). 
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Figure 1 – Flow chart of the screening pilot project for con-
genital adrenal hyperplasia in Minas Gerais with cutoff val-
ues for 17OHP (17-hydroxyprogesterone) measurements on 
ﬁlter paper.
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The confirmation of 17OHP level alteration in a pe-
ripheral blood sample was obtained by measurement in 
a reference laboratory, by radioimmunoassay (reference 
value for the first month: 17-204 ng/dL for females and 
53-186 ng/dL for males). Children with elevated serum 
17OHP, suggestive clinical features, and alterations in oth-
er complementary tests (ionogram and androgens: andro-
stenedione and testosterone) had the diagnosis of 21-OH 
deficiency confirmed. These and the indeterminate cases 
were followed at the abovementioned outpatient pediat-
ric endocrinology clinic. Children with positive screening 
who did not have CAH were referred to pediatric follow-
up in their own municipalities after normalization of hor-
mone levels.
The information on weight and gestational age at birth 
of patients undergoing follow-up were obtained through 
medical records. 
Throughout the project, information was provided to 
the primary care teams, and parents and families were 
instructed about the inclusion of CAH screening in the 
routine Guthrie test as a pilot study by several means of 
communication, including video conferences. NUPAD 
employees were responsible for reporting positive test 
results, requesting additional blood samples, setting up 
medical appointments, arranging transportation for time-
ly consultations, and forwarding samples and supplying 
medications, when necessary, in addition to welcoming 
and housing children and families at a support center. 
STATISTICAL ANALYSIS 
For data analysis Microsoft SQL Management Studio 
Express from Microsoft SQL Server 2000 software was 
used. The disease incidence was estimated by the number 
of children with confirmed disease divided by the total 
number of neonates screened in the period. The values 
of 17OHP did not show a normal distribution, and were 
presented as medians and analyzed by nonparametric 
tests: Mann-Whitney and Kruskal-Wallis test were used 
to compare two and four independent groups in relation 
to the median, respectively. For multiple comparisons, the 
correction of significance level was performed. The signifi-
cance level was set at 5% (p < 0.05). Percentiles of 17OHP 
values  were calculated from the first sample on filter paper 
of all children, and separately according to the birth weight 
(<1,500 g, 1,500 to 1,999 g, 2,000 to 2,499 g, and ≥ 2,500 g) 
using Microsoft Excel 2007 software. The positive predic-
tive value (PPV) of the evaluation, the recall rate (RR), and 
the sensitivity and specificity of the test were calculated. 
RESULTS
A total of 159,415 newborns were screened for CAH be-
tween September 2007 and May 2008 by the PETN-MG. 
The age at screening was 8 ± 14 days, with a median of six 
days. Sixteen children started treatment for CAH, ten of 
whom were males. During clinical follow-up, eight chil-
dren had no confirmation of the diagnosis of CAH and 
therapy was discontinued, which resulted in an incidence 
of disease for this population of 1:19,939. Of the eight pa-
tients, five were females and three were males, and 75% 
had the salt-wasting form. The mean age of the affected 
children at the screening was 7 ± 2 days. The median age at 
start of treatment was 39 days (range 13-581). 
Between September 1, 2007 and February 26, 2008 
106,476 newborns were screened and seven children were 
considered to be affected at the follow-up (incidence of 
1:15,211). According to the established criteria, 103,269 
newborns were evaluated by the cutoff value of 80 nmol/L 
and 1% of them (n = 1,036) had the first sample above the 
reference value. During the same period, the birth weight 
of 12.5% of all newborns was registered. Of 13,298 records, 
23% were reported as low birth weight. Of the 3,207 new-
borns with low weight, assessed by the cutoff value of 160 
nmol/L, 11% (n = 354) had the first sample above the ref-
erence value.
A total of 380 children were recalled (RR = 0.36%) 
for medical consultation. Of these, 315 children were fol-
lowed, of which 63% were premature and/or had low birth 
weight, according to the study of the medical files.
The test sensitivity, considering the absence of false-
negative records, was 100%, with a specificity of 99.6%. 
The positive predictive value of the assessment was 2.2%. 
The 99th percentile (p99) of 17OHP of all newborns 
screened in the first sample on filter paper was 108 nmol/L. 
The 17OHP distribution of the first sample on filter pa-
per, in percentiles, was calculated for each weight group 
at birth: < 1500 g (n = 748), 1,500 to 1,999 g (n = 971), 
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Figure 2 – 50th and 99th percentiles of 17OHP on ﬁlter 
paper (17-hydroxyprogesterone – nmol/L) for groups of 
children distributed according to birth weight.
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2,000 to 2,499 g (n = 1,357) and ≥ 2,500 g (n = 10,222), 
and this distribution is shown in Figure 2. The percentiles 
p50 and p99, were respectively 96 and 344 nmol/L, 58 and 
260 nmol/L, 47 and 221 nmol/L, 35 and 109 nmol/L for 
each weight group. There was a statistically significant dif-
ference of the medians (p50) of 17OHP between the four 
weight groups (p < 0.001) and also when the groups were 
compared two by two (p < 0.001).
By adjusting the cutoff value for 17OHP, in accordance 
with the p99 for newborns with appropriate weight, to 
110 nmol/L and that of newborns with low birth weight 
(< 2500 g) to 220 nmol/L, it was calculated that there 
would be a 76% decrease in referrals for medical consulta-
tion after the first sample collection. 
DISCUSSION
Neonatal screening for CAH is not yet universally ac-
cepted, and is included in the group that generates con-
troversy regarding its inclusion in screening programs. 
The diseases screened in each country, or even in differ-
ent regions of a country, depend on health policy deci-
sions based on epidemiological, ethnic, social, economic, 
and ethical aspects5. 
Although the cost-effectiveness of screening for CAH 
is still debated, the benefits must be considered, especially 
in developing countries with incompletely consolidated 
health systems that do not favor the performance of accu-
rate and fast diagnoses, as required by this disease.
It has been reported that screening for CAH is effective 
to promote a 74% to 86% decrease in mortality in patients 
with the disease12. Moreover, the families of sick children 
describe a more stressful experience when the diagnosis 
is made based on the clinical manifestations and not by 
neonatal screening. Parental discomfort with screening 
occurs when the goal of early detection of potentially af-
fected children is not understood13. 
Screening for CAH is part of screening programs in 
France, Sweden, Switzerland, New Zealand, Israel, Ice-
land, Austria, Germany and in several U.S. states, includ-
ing Alaska, a pioneer in this screening4 and, more recent-
ly, in Argentina14. 
In Brazil, routine screening for CAH is performed 
only in Goiás and Santa Catarina. The incidence of 
CAH found in Goiás was 1:10,325, lower than that 
previously found in southern Brazil, of 1:7,53315. 
The accomplishment of the pilot program for CAH in 
Minas Gerais was possible due to the already established 
PETN structure implemented in 1993 and coordinated 
by the NUPAD16.
The PETN-MG is linked to the National Neonatal 
Screening Program (PNTN) of the Brazilian Ministry of 
Health17, implemented in 2001, aiming at 100% coverage 
of live births for phenylketonuria, congenital hypothy-
roidism, sickle-cell anemia, and cystic fibrosis.
The PNTN defines the process of newborn screening 
in five steps, as recommended by the American College of 
Medical Genetics18, i.e., laboratory testing, investigation of 
suspected cases, diagnostic confirmation, treatment, and 
follow-up by a multidisciplinary team. The implementa-
tion is performed in three phases, according to the level 
of organization and coverage of each state. In phase I, the 
diseases screened for are phenylketonuria and congenital 
hypothyroidism. In phase II, sickle cell anemia is included, 
and in phase III, cystic fibrosis is included19. Currently, 
only four Brazilian states are in phase III (Minas Gerais, 
Santa Catarina, Paraná, and Espírito Santo). According to 
2007 data, the population coverage of neonatal screening 
in Brazil is 78.9% and some states report coverage > 95% 
for the four diseases. PNTN still has room for improve-
ment and the possibility of expanding the range of diseases 
to be screened is considered, if there is a proven benefit for 
the population20.
The PETN-MG has a population coverage of 94.6% 
(2007 data), and it has been in phase III since 2003, show-
ing the feasibility of implementing new screening pro-
grams, as other Brazilian states.
The available tests for CAH neonatal screening include 
radioimmunoassay (RIA), initially described by Pang et 
al.21, fluorimetry, and tandem mass spectrometry (TMS). 
RIA is currently underutilized due to large interference of 
other metabolites, especially 17-hydroxypregnenolone22. 
On the other hand, TMS is not widely used, despite its 
higher specificity, due to the need for large capital invest-
ment. Fluorimetry is the most often used technique, in-
cluding in the Brazilian programs. 
In the pilot study conducted in MG, measurements 
were performed using the UMELISA 17-OH Proges-
terona NEONATAL® assay, resulting from the combina-
tion of the high sensitivity of the microElisa tests (ELISA 
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ultramicro-Umelisa) and the use of ultra-microvolumes 
for samples and reagents (Micro Ultra Analytic System, 
SUMA). Studies on filter paper showed that the technique 
provides superior results to RIA, with less interference, 
good precision, and accuracy, allowing the study of a large 
number of samples at the lowest possible cost23,24. These 
characteristics, combined with cost-effectiveness for large-
scale screening and the use of the technique with good re-
sults for tests, e.g., the congenital hypothyroidism program 
in MG, were responsible for the choice of this method for 
the pilot study. The use of an immunoenzymatic assay in 
pilot programs of screening for CAH has been previously 
described in China25. 
The great challenge related to neonatal screening for 
CAH is the definition of an appropriate cutoff for 17OHP 
in the population. Interference caused by other ste-
roids, especially sulfates26 and transient elevations in 
17OHP levels in preterm newborns or those with low 
birth weight may generate large numbers of false posi-
tive results, causing increased costs and parental stress, 
affecting the real perception of parents regarding the 
child’s health27.  
During the pilot project in MG, it was observed that 
the cutoff value initially used resulted in a great number 
of false positive results. 
The categorization of 17OHP reference values  ac-
cording to birth weight and gestational age is a strategy 
used to reduce the false-positive rate. In the state of Wis-
consin, USA (1997), division into four weight categories 
increased the positive predictive value for screening by 
ten times, without impairing test sensitivity, with a de-
crease of 50% in the recall rate8. 
Olgemöller, in the German region of Bavaria, also 
proposed a screening categorization, based on five rang-
es of birth weight and according to age adjusted at the 
collection for weight > 2,500g. Thus, the specificity was 
99.3%, the positive predictive value increased from 0.84% 
to 1.29% (1.5 times), and the false-positive rate decreased 
from 1.12% to 0.73%7.
In Brazil, rates of prematurity and low birth weight 
are highly variable, depending on the region evaluated. 
According to the Interagency Network for Health and 
Health Information (Rede Interagencial de Saúde e In-
formação para a Saúde – RIPSA/DATASUS-2005), the 
Brazilian total rate of prematurity was 6.6% and of these, 
37.4% also had low birth weight. The worldwide trend 
is of stabilization of the percentage of children with low 
birth weight and increased prematurity due to the im-
provement of perinatal and neonatal care. In 2007, an 
overall rate of 9.1% was recorded for prematurity in the 
country (Instituto Nacional de Estatística)28, showing the 
importance of adjusting the cutoff values  of 17OHP for 
this population.
The reference adjustment for sick children and in-
formation obtained regarding birth weight were neces-
sary for the discussion of a cutoff value suitable for each 
group. Although the screening program in Minas Gerais 
is well established, information on birth weight was not 
compulsory until the pilot project for CAH was started. 
During the study period, information on weight was ob-
tained for 12.5% of children, of whom 23% had low birth 
weight and only 0.5% were premature, which possibly 
represents an inadequate quality of information. 
Nevertheless, it was observed that while only 1% of 
healthy children with normal weight at birth had a posi-
tive first sample, 11% of premature newborns and or 
those with low birth weight showed this result, suggest-
ing inadequacy of the reference value for 17OHP and the 
need to change the cutoff value for the project’s feasibility. 
The principles postulated by Wilson-Jungner were 
observed during the pilot project, which suggest the ap-
propriate cost-effectiveness of the program2,29,30: high in-
cidence of disease (< 1:20,000), test with good sensitiv-
ity and specificity (approximately 100%), recall rate that 
is feasible for the program organization, and prospect of 
significantly reducing mortality of the salt-wasting form31. 
These findings help to reinforce the possibility of in-
cluding congenital adrenal hyperplasia in the PNTN an-
nounced at a hearing held on June 6, 2011 by the Minis-
try of Health32. 
The results justify the performance of newborn 
screening for CAH and suggest the possibility of extend-
ing the screening to other Brazilian states. The use of the 
cutoff values suggested for 17OHP, according to birth 
weight, showed to be a cost-effective measure for pro-
gram implementation. 
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